MNTA Share Price

Open 14.45 Change Price %
High 15.12 1 Day -0.25 -1.74
Low 14.00 1 Week 0.00 0.00
Close 14.10 1 Month 0.55 4.06
Volume 933740 1 Year 0.45 3.30
52 Week High 19.90
52 Week Low 12.10
MNTA Important Levels
Resistance 2 15.14
Resistance 1 14.71
Pivot 14.41
Support 1 13.49
Support 2 13.06
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)

MNTA Technical Analysis 3
As on 31st Oct 2017 MNTA Share Price closed @ 14.10 and we RECOMMEND Sell for LONG-TERM with Stoploss of 15.58 & Sell for SHORT-TERM with Stoploss of 15.73 we also expect STOCK to react on Following IMPORTANT LEVELS.
MNTA Target for December
1st Target up-side 17.64
2nd Target up-side 20.13
3rd Target up-side 22.61
1st Target down-side 10.56
2nd Target down-side 8.07
3rd Target down-side 5.59
MNTA Other Details
Segment EQ
Market Capital 681705792.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.momentapharma.com
MNTA Address
MNTA
675 West Kendall Street
Cambridge, MA 02142
United States
Phone: 617-491-9700
Fax: 617-621-0431
MNTA Latest News
Interactive Technical Analysis Chart Momenta Pharmaceuticals, Inc. ( MNTA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Momenta Pharmaceuticals, Inc.
MNTA Business Profile
Momenta Pharmaceuticals, Inc. (Momenta) is a biotechnology company specializing in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). This results in a diversified product pipeline of complex generic, follow-on biologic (FOB) and novel drugs. The Company�s complex generic programs target marketed products, which were originally approved by the United States Food and Drug Administration (FDA) as New Drug Applications (NDAs). Its M356, is designed to be a generic version of Copaxone (glatiramer acetate injection), a drug that is indicated for the reduction of the frequency of relapses in patients with Relapsing-Remitting Multiple Sclerosis (RRMS). During the year ended December 31, 2011, it acquired the assets of Virdante. On February 13, 2012 it entered into a global collaboration (Baxter Agreement) with Baxter International Inc.